United States: First Round Of BPCIA Litigation: Declaratory Judgment Act Can’t Be Used To Avoid The "Patent Dance"

Last Updated: February 25 2015
Article by Aron Fischer

As the 1984 Hatch-Waxman Act did for generic small-molecule drugs, the Biologics Price Competition and Innovation Act of 2009 created a new regulatory pathway for the approval of biosimilar or interchangeable versions of biological medicines.  The BPCIA also created a new legal framework for resolving associated patent disputes, sometimes called the "patent dance" because of its intricate sequence of exchanges.  Five years after the passage of the BPCIA, litigation concerning the statute's patent procedures has recently begun to reach the courts.  To date, there have been four reported decisions (arising from three cases) addressing patent disputes between biosimilar makers and patent holders: a Northern District of California decision (Sandoz Inc. v. Amgen Inc., 2013 U.S. Dist. LEXIS 161233 (N.D. Ca. Nov. 12, 2013) that was affirmed by the Federal Circuit (773 F.3d 1274 (2014)) and two cases from the Southern District of New York (Celltrion Healthcare Co., Ltd. v. Kennedy Trust for Rheumatology Research, 2014 U.S. Dist. LEXIS 166491 (S.D.N.Y. Dec. 1, 2014) and Hospira, Inc. v. Janssen Biotech, Inc., 2014 U.S. Dist. LEXIS 166498 (S.D.N.Y. Dec. 1, 2014)).*

Although these are the first cases addressing BPCIA patent disputes, in none of them did the parties actually follow the statutory patent dispute resolution procedures. Rather, all were declaratory judgment actions filed by biosimilar makers (or their marketing partners), before the statutory patent dance had begun, seeking declarations that their anticipated biosimilar products would not infringe valid patents.  The biosimilars makers contended that though their applications had not yet been accepted for review by FDA (the event which triggers the patent dance), they were far enough along to create concrete and immediate disputes with the holders of patents on the biological products.

The biosimilars makers' efforts to bypass the BPCIA patent dance provisions have not been successful.  In each of the reported cases, the patent holders moved to dismiss on the ground that the actions were premature.  And in each case, the courts agreed and dismissed the complaints for lack of subject matter jurisdiction.

All three district court decisions relied on the same two grounds: first, there was no justiciable case or controversy under the Declaratory Judgment Act and Article III of the Constitution, and second, the biosimilar maker could not file a declaratory judgment action without first exhausting the BPCIA patent dispute resolution procedures.  In the only case to reach the Federal Circuit, Sandoz v. Amgen, the Federal Circuit affirmed on justiciability grounds, and expressly declined to address the BPCIA.  The other two dismissals, in the Celltrion and Hospira cases, were not appealed.  The existence of a statutory exhaustion requirement therefore remains an open question as far as binding Federal Circuit precedent is concerned.

The reasoning of the cases, however, leaves little room for declaratory judgment actions before a biosimilar application is accepted for review by FDA.

The BPCIA expressly limits the ability of biosimilar applicants to bring declaratory judgment actions in certain circumstances (see 42 U.S.C. § 262(l)(9)).  These express limitations, however, are conditioned on the completion, or failure to complete, particular steps in the statutory patent dance. The biosimilars makers contended that because the patent dance begins only after FDA accepts an application for review, the statute does not prohibit declaratory judgment actions filed before the patent dance starts.  The district courts rejected this statutory argument, holding that the BPCIA procedures cannot be circumvented by filing an early declaratory judgment action.

Although the Federal Circuit did not address the statutory question in Sandoz v. Amgen, it relied on the fact that Sandoz had not yet filed its application to hold that there was no justiciable case or controversy.   The Federal Circuit said that it was not "adopting a categorical rule" that no case or controversy could be demonstrated when no application had been filed.  But it also said that it was "aware of no decision in which we have found a case or controversy when the only activity that would create exposure to potential infringement liability was a future activity requiring an FDA approval that had not yet been sought."  In the Celltrion and Hospira cases, Judge Crotty of the Southern District of New York was similarly skeptical that a biosimilar maker could establish a ripe controversy before its application had been accepted for review.  In light of this reasoning, it may end up being a moot point whether the BPCIA independently prohibits pre-application declaratory judgment actions.  Based on the case law so far, such actions do not appear to be justiciable under Article III.

Because Article III justiciability is a fact-intensive inquiry, and because BPCIA's patent dance contains permutations that have not yet been addressed by the courts, there is likely to be further litigation over the availability of declaratory judgments under the BPCIA.  The first round of BPCIA litigation, however, suggests that biosimilar makers – or, for that matter, patent holders – may not avoid the BPCIA patent dance simply by filing declaratory judgment actions before it starts.

*Patterson Belknap was co-counsel for the declaratory judgment defendants in the Hospira action.  As discussed in the text, the action was dismissed and the dismissal was not appealed.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.